synthesis
character
polyoxometal
cs
k
na
siw
nb
antihepat
b
viru
hbv
properti
use
cell
methylthiazol
tetrazolium
assay
use
evalu
growth
inhibitori
effect
compound
cell
use
elisa
realtim
pcr
respect
presenc
extracellular
hepat
b
surfac
antigen
hbsag
e
antigen
hbeag
hbv
dna
measur
level
intracellular
hbv
dna
mrna
determin
use
southern
blot
reversetranscriptionpcr
respect
intracellular
distribut
antigen
measur
western
blot
lmoll
concentr
commerciallyavail
hepat
b
drug
adefovir
dipivoxil
adv
requir
achiev
cytotox
cultur
cell
cc
day
nine
contrast
lmoll
compound
requir
result
treatment
cell
compound
effect
suppress
secret
hbv
antigen
hbv
dna
dosedepend
timedepend
manner
ic
valu
determin
lmoll
hbsag
lmoll
hbeag
lmoll
supernat
hbv
dna
day
nine
postexposur
oppos
lmoll
respect
adv
intracellular
hbv
dna
mrna
antigen
also
found
decreas
compound
dose
adv
yield
significantli
less
robust
inhibitori
effect
compound
clear
hbv
hepat
cell
may
repres
therapeut
agent
treat
hbv
infect
approxim
billion
peopl
worldwid
infect
hepat
b
million
live
chronic
infect
hbv
belong
hepadnavirida
famili
noncytopath
dna
viru
replic
via
reversetranscript
rna
intermedi
pregenom
rna
pgrna
intermedi
produc
insid
cellular
nucleu
next
pgrna
export
cytoplasm
virallyencod
polymeras
convert
pgrna
minusstrand
dna
ultim
doublestrand
relax
circular
dna
molecul
gener
life
cycl
place
hbv
larger
famili
retrovirus
character
reversetranscript
activ
involv
rna
intermedi
chronic
hepat
b
patient
commonli
treat
either
interferon
alpha
infa
nucleosid
analog
lamivudin
adefovir
entecavir
telbivudin
synthet
reversetranscriptas
inhibitor
infa
inhibit
viral
replic
act
immunomodul
limit
effect
respons
rate
costli
elicit
seriou
undesir
side
effect
mediat
revers
inhibit
event
continu
treatment
associ
develop
drugresist
hbv
variant
patient
year
treatment
adefovir
entecavir
telbivudin
use
strain
detect
howev
resist
drug
also
report
combin
therapi
nucleosid
analog
plu
infa
promis
approach
may
yield
addit
synergist
effect
may
reduc
emerg
resist
strain
unfortun
seriou
side
effect
associ
agent
use
remain
may
even
compound
therefor
critic
develop
therapeut
agent
improv
efficaci
minim
side
effect
polyoxometal
pom
metaloxid
cluster
anion
applic
potenti
electron
magnet
homogen
heterogen
photocatalysi
medicin
act
antitumor
viral
bacteri
agent
mani
studi
found
evid
pom
inhibit
replic
see
front
matter
abbrevi
si
select
index
concentr
inhibit
hbv
dna
replic
hbsag
hbeag
secret
concentr
achiev
cytotox
cultur
cell
adv
adefovir
dipivoxil
synthesis
character
polyoxometal
cs
k
na
siw
nb
antihepat
b
viru
hbv
properti
use
cell
methylthiazol
tetrazolium
assay
use
evalu
growth
inhibitori
effect
compound
cell
use
elisa
realtim
pcr
respect
presenc
extracellular
hepat
b
surfac
antigen
hbsag
e
antigen
hbeag
hbv
dna
measur
level
intracellular
hbv
dna
mrna
determin
use
southern
blot
reversetranscriptionpcr
respect
intracellular
distribut
antigen
measur
western
blot
lmoll
concentr
commerciallyavail
hepat
b
drug
adefovir
dipivoxil
adv
requir
achiev
cytotox
cultur
cell
cc
day
nine
contrast
lmoll
compound
requir
result
treatment
cell
compound
effect
suppress
secret
hbv
antigen
hbv
dna
dosedepend
timedepend
manner
ic
valu
determin
lmoll
hbsag
lmoll
hbeag
lmoll
supernat
hbv
dna
day
nine
postexposur
oppos
lmoll
respect
adv
intracellular
hbv
dna
mrna
antigen
also
found
decreas
compound
dose
adv
yield
significantli
less
robust
inhibitori
effect
compound
clear
hbv
hepat
cell
may
repres
therapeut
agent
treat
hbv
infect
elsevi
ltd
right
reserv
approxim
billion
peopl
worldwid
infect
hepat
b
million
live
chronic
infect
hbv
belong
hepadnavirida
famili
noncytopath
dna
viru
replic
via
reversetranscript
rna
intermedi
pregenom
rna
pgrna
intermedi
produc
insid
cellular
nucleu
next
pgrna
export
cytoplasm
virallyencod
polymeras
convert
pgrna
minusstrand
dna
ultim
doublestrand
relax
circular
dna
molecul
gener
life
cycl
place
hbv
larger
famili
retrovirus
character
reversetranscript
activ
involv
rna
intermedi
chronic
hepat
b
patient
commonli
treat
either
interferon
alpha
infa
nucleosid
analog
lamivudin
adefovir
entecavir
telbivudin
synthet
reversetranscriptas
inhibitor
infa
inhibit
viral
replic
act
immunomodul
limit
effect
respons
rate
costli
elicit
seriou
undesir
side
effect
mediat
revers
inhibit
event
continu
treatment
associ
develop
drugresist
hbv
variant
patient
year
treatment
adefovir
entecavir
telbivudin
use
strain
detect
howev
resist
drug
also
report
combin
therapi
nucleosid
analog
plu
infa
promis
approach
may
yield
addit
synergist
effect
may
reduc
emerg
resist
strain
unfortun
seriou
side
effect
associ
agent
use
remain
may
even
compound
therefor
critic
develop
therapeut
agent
improv
efficaci
minim
side
effect
polyoxometal
pom
metaloxid
cluster
anion
applic
potenti
electron
magnet
homogen
heterogen
photocatalysi
medicin
act
antitumor
viral
bacteri
agent
mani
studi
found
evid
pom
inhibit
replic
abbrevi
si
select
index
concentr
inhibit
hbv
dna
replic
hbsag
hbeag
secret
concentr
achiev
cytotox
cultur
cell
adv
adefovir
dipivoxil
rna
virus
dna
virus
particular
decreas
activ
human
immunodefici
viru
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
herp
simplex
viru
observ
mechan
antivir
action
remain
fulli
elucid
may
occur
life
cycl
stage
includ
viral
adsorpt
penetr
reversetranscript
niobiumsubstitutedheteropolytungst
shown
potent
activ
minim
cytotox
therefor
sought
investig
antivir
effect
pom
cs
k
na
siw
nb
use
cell
secret
hbsag
hbeag
complet
dna
particl
result
indic
compound
exhibit
strong
antivir
activ
hbv
virus
low
cytotox
indic
potenti
medicin
candid
hbv
virus
date
studi
hepat
b
viru
treatment
pom
report
yet
potent
antivir
activ
molecul
promis
clinic
applic
xray
crystallographi
shown
compound
consist
polyoxoanion
siw
nb
alkali
cation
isol
water
molecul
tabl
compound
polyoxoanion
siw
nb
exhibit
wellknown
keggin
structur
quit
similar
found
previous
describ
pom
determin
whether
compound
suppress
hbv
product
induc
cytotox
cell
expos
drug
cellular
viabil
analyz
mtt
assay
appar
cytotox
observ
day
treatment
compound
lower
concentr
lmoll
fig
find
suggest
suppress
activ
compound
supernat
viral
dna
antigen
level
result
induc
cytotox
cc
compound
determin
lmoll
day
nine
fig
correspond
cc
adv
lmoll
antihbv
activ
compound
adv
investig
compar
cell
treat
variou
concentr
compound
adv
secret
hbeag
hbsag
hbv
dna
found
significantli
less
compar
level
detect
supernat
nontreat
control
fig
shown
figur
treatment
lmoll
compound
significantli
reduc
hbsag
hbeag
dosedepend
manner
compar
nontreat
control
p
dose
lmoll
abl
reduc
hbv
dna
day
treatment
data
clearli
show
inhibitori
activ
compound
hbsag
hbeag
hbv
dna
promot
time
vs
nontreat
control
p
inhibitori
activ
compound
ninth
day
treatment
higher
day
seven
notabl
result
indic
product
hbsag
hbeag
slightli
suppress
low
dose
compound
supernat
hbv
dna
level
dramat
suppress
dosag
ic
compound
adv
day
shown
tabl
compound
si
greater
adv
day
nine
especi
hbv
dna
consid
interestingli
day
day
end
exposur
drug
inhibit
rate
compound
serum
hbsag
hbeag
hbv
dna
lower
observ
day
nine
howev
lower
day
seven
indic
compound
may
persist
effect
suppress
hbv
contrast
inhibit
rate
adv
serum
hbsag
hbeag
hbv
dna
declin
steadili
lower
day
seven
fig
decreas
significantli
compar
detect
neg
control
group
p
peak
inhibit
rate
mrna
achiev
dose
lmoll
determin
compar
level
detect
nontreat
control
group
moreov
level
mrna
lower
detect
cell
treat
similar
dose
adv
p
result
suggest
compound
act
detriment
impact
viral
dna
replic
viral
mrna
transcript
cell
antihbv
effect
compound
seem
least
partial
similar
adv
suppress
effect
robust
next
investig
whether
compound
abl
reduc
hbsag
hbcag
protein
cell
treat
compound
day
western
blot
analysi
antihbsag
antihbcag
bactin
indic
drug
caus
dosedepend
decreas
level
intracellular
product
hbsag
hbcag
compar
neg
control
fig
dose
adv
treatment
abl
inhibit
antigen
extent
pom
neg
charg
inorgan
substanc
princip
compris
oxid
anion
earli
transitionmet
cation
sever
pom
character
broad
rang
antivir
activ
particular
complex
shown
excel
inhibitori
activ
human
immunodefici
virus
herp
simplex
viru
influenza
viru
pom
nontox
mammalian
cell
appear
readili
induc
drugresist
strain
target
pathogen
promis
candid
develop
human
therapeut
agent
research
pom
small
molecul
drug
becom
heavili
pursu
short
studi
period
number
pom
synthes
evalu
potenti
antivir
activ
studi
examin
antihbv
activ
compound
vitro
employ
cell
line
wide
use
model
evalu
antihbv
drug
contain
two
copi
hbv
genom
compound
elicit
dosedepend
timedepend
inhibitori
effect
secret
hbv
dna
hbsag
hbeag
antigen
day
treatment
lower
dose
compound
requir
effect
inhibit
secret
hbv
dna
inhibit
secret
antigen
effect
compound
inhibit
hbv
activ
cell
determin
cytotox
event
possibl
compound
act
export
virion
outer
protein
coat
though
mechan
mediat
antivir
effect
compound
remain
unclear
deduc
compound
might
block
secret
hbv
contain
nucleocapsid
destabil
hbv
dnacontain
nucleocapsid
observ
inhibit
rate
hbsag
hbeag
hbv
dna
depend
concentr
time
exposur
compound
adv
interestingli
vitro
antihbv
properti
compound
rebound
serum
hbv
dna
hbsag
hbeag
robust
adv
indic
evalu
treat
cell
day
termin
treatment
charact
sustain
activ
may
signific
clinic
implic
compound
support
effort
develop
compound
antihbv
drug
treatment
patient
chronic
hbv
infect
remain
import
clinic
challeng
persist
hbv
viraemia
strongli
associ
develop
liver
cirrhosi
hepatocellular
carcinoma
complet
resolut
infect
critic
current
avail
treatment
option
howev
suppress
viral
replic
fortun
nucleosidetid
analogbas
therapeut
associ
lower
rate
antivir
drug
resist
longterm
induc
rapid
virolog
respons
howev
still
demand
new
improv
therapi
complet
clear
hbv
infect
adv
drug
competit
inhibit
hbv
polymeras
structur
similar
datp
also
known
reduc
hbv
dna
hbsag
vitro
vivo
phosphoryl
event
facilit
physic
incorpor
nascent
viral
dna
activ
hbv
polymeras
replic
studi
observ
appar
reduct
level
intracellular
hbv
intermedi
mrna
respons
compound
treatment
therefor
surpris
level
antigen
translat
mrna
reduc
underli
molecular
mechan
compound
act
viral
polymeras
process
protein
express
remain
unknown
elucid
investig
perform
experi
use
nonhepb
gene
express
cell
instead
hepb
gene
express
cell
cytotox
observ
day
exposur
compound
adv
dosag
use
data
shown
anticip
hbsag
hbeag
viral
dna
detect
supernat
neg
control
cell
intracellular
hbv
dna
mrna
antigen
detect
either
result
neg
control
cell
confirm
result
specif
hepb
uniqu
express
cell
attract
featur
pom
develop
therapeut
nearli
everi
molecular
properti
mediat
recognit
reactiv
pom
target
biolog
macromolecul
manipul
exampl
fine
tune
alter
made
redox
potenti
polar
shape
surfac
charg
distribut
acid
organ
derivat
metal
substitut
extend
number
pom
avail
moreov
pomsbas
raw
materi
rel
inexpens
technic
simpl
gener
amplifi
henc
promis
signific
econom
technic
advantag
current
avail
pharmaceut
sinc
regulatori
mechan
involv
viral
replic
quit
differ
protein
express
hbv
antigen
observ
compound
inhibit
hbv
dna
replic
rna
transcript
also
hbv
antigen
secret
indic
might
least
three
target
compound
antivir
activ
howev
exact
mechan
antihbv
activ
compound
remain
complet
understood
requir
investig
conclus
present
studi
demonstr
compound
effect
inhibit
hbv
antigen
secret
hbv
replic
dosedepend
timedepend
manner
vitro
compound
therefor
worthi
investig
excel
candid
potenti
clinic
applic
select
index
determin
cc
ic
valu
cytotox
concentr
compound
adv
reduc
cell
viabil
cc
b
concentr
compound
adv
need
inhibit
